Addressing phenoconversion: The Achilles' heel of personalized medicine

British Journal of Clinical Pharmacology

Volumn 79, Issue 2, 2015, Pages 222-240

  Shah, Rashmi R ^a   Smith, Robert L ^b  

^a Rashmi Shah Consultancy Ltd   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

genotype phenotype mismatch; personalized medicine; pharmacogenetic association studies; pharmacogenetics; phenoconversion; phenotyping probes

Indexed keywords

AMIODARONE; ANALGESIC AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2D6 INHIBITOR; DEBRISOQUINE; DRUG METABOLIZING ENZYME; FLUOXETINE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; WARFARIN; DRUG;

ALLELE; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE MISMATCH; HAPLOTYPE; HUMAN; INHERITANCE; METABOLIC CAPACITY; METABOLIC RATIO; METABOLISM; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOKINETICS; PHENOCONVERSION; PHENOTYPE; POPULATION GENETICS; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; SINGLE NUCLEOTIDE POLYMORPHISM; DOSE RESPONSE; DRUG INTERACTION; GENETIC POLYMORPHISM; GENETICS; PROCEDURES;

CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GENOTYPE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; PRECISION MEDICINE;

EID: 84941042620     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12441     Document Type: Article

References (147)

1. Brockmöller J, Kirchheiner J, Meisel C, Roots I,. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 2000; 1: 125-151.
2. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M,. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79: 103-113.
3. Kirchheiner J, Bertilsson L, Bruus H, Wolff A, Roots I, Bauer M,. Individualized medicine-implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry 2003; 36 (Suppl. 3): S235-243.
4. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP,. Genetic variations in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004; 5: 895-931.
5. Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, Sai K, Ohno Y, Saito Y, Sawada J,. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 2004; 19: 83-95.
6. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmöller J,. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442-473.
7. Dutch Pharmacogenetics Working Group. Genotype to phenotype translation 'CYP2D6 Genotype to Phenotype'. Available at http://www.pharmgkb.org/page/dpwg (last accessed 23 April 2014).
8. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS,. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83: 234-242.
9. Kirchheiner J,. CYP2D6 phenotype prediction from genotype: which system is the best? Clin Pharmacol Ther 2008; 83: 225-227.
10. Hicks JK, Swen JJ, Gaedigk A,. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Curr Drug Metab 2014; 15: 218-232.
11. Wennerholm A, Dandara C, Sayi J, Svensson JO, Abdi YA, Ingelman-Sundberg M, Bertilsson L, Hasler J, Gustafsson LL,. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther 2002; 71: 77-88.
12. Bogni A, Monshouwer M, Moscone A, Hidestrand M, Ingelman-Sundberg M, Hartung T, Coecke S,. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. Toxicol in Vitro 2005; 19: 621-629.
13. Brøsen K, Gram LF, Haghfelt T, Bertilsson L,. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol 1987; 60: 312-314.
14. Ayesh R, Dawling S, Hayler A, Oates NS, Cholerton S, Widdop B, Idle JR, Smith RL,. Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers. Chirality 1991; 3: 14-18.
15. Vormfelde SV, Brockmöller J, Bauer S, Herchenhein P, Kuon J, Meineke I, Roots I, Kirchheiner J,. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clin Pharmacol Ther 2009; 86: 54-61.
16. Oshiro C, Thorn CF, Roden DM, Klein TE, Altman RB,. KCNH2 pharmacogenomics summary. Pharmacogenet Genomics 2010; 20: 775-777.
17. Shah RR,. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf 2004; 27: 145-172.
18. Marsenic O,. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009; 53: 875-883.
19. Weber O, Bischoff H, Schmeck C, Böttcher MF,. Cholesteryl ester transfer protein and its inhibition. Cell Mol Life Sci 2010; 67: 3139-3149.
20. Division of Clinical Pharmacology Indiana University P450 drug interaction table. Available at http://medicine.iupui.edu/clinpharm/DDIs/table.aspx (last accessed 17 January 2014).
21. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA,. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther 2013; 17: 165-184.
22. Olesen C, Harbig P, Barat I, Damsgaard EM,. Absence of 'over-the-counter' medicinal products in on-line prescription records: a risk factor of overlooking interactions in the elderly. Pharmacoepidemiol Drug Saf 2013; 22: 145-150.
23. Williamson EM,. Interactions between herbal and conventional medicines. Expert Opin Drug Saf 2005; 4: 355-378.
24. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, Duan W, Koh HL, Zhou S,. Herb-drug interactions: a literature review. Drugs 2005; 65: 1239-1282.
25. Goldstein LH, Elias M, Ron-Avraham G, Biniaurishvili BZ, Madjar M, Kamargash I, Braunstein R, Berkovitch M, Golik A,. Consumption of herbal remedies and dietary supplements amongst patients hospitalized in medical wards. Br J Clin Pharmacol 2007; 64: 373-380.
26. Tarirai C, Viljoen AM, Hamman JH,. Herb-drug pharmacokinetic interactions reviewed. Expert Opin Drug Metab Toxicol 2010; 6: 1515-1538.
27. Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM,. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. J Clin Pharmacol 2001; 41: 443-451.
28. Nakashima D, Takama H, Ogasawara Y, Kawakami T, Nishitoba T, Hoshi S, Uchida E, Tanaka H,. Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. J Clin Pharmacol 2007; 47: 1311-1319.
29. Pope LE, Khalil MH, Berg JE, Stiles M, Yakatan GJ, Sellers EM,. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J Clin Pharmacol 2004; 44: 1132-1142.
30. Laine K, Tybring G, Härtter S, Andersson K, Svensson JO, Widén J, Bertilsson L,. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther 2001; 70: 327-335.
31. Dalén P, Dahl M, Andersson K, Bertilsson L,. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes. Br J Clin Pharmacol 2000; 49: 180-184.
32. Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J,. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 2002; 22: 1001-1006.
33. O'Neil WM, Gilfix BM, Markoglou N, Di Girolamo A, Tsoukas CM, Wainer IW,. Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome. Eur J Clin Pharmacol 2000; 56: 231-240.
34. Jones AE, Brown KC, Werner RE, Gotzkowsky K, Gaedigk A, Blake M, Hein DW, van der Horst C, Kashuba AD,. Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol 2010; 66: 475-485.
35. Mitchell SC, Shah RR, Clements DG, Smith RL,. Changes in debrisoquine hydroxylation capacity following liver surgery. Hum Exp Toxicol 1994; 13: 537-541.
36. Monek O, Paintaud G, Bechtel Y, Miguet JP, Mantion G, Bechtel PR,. Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6∗3 and CYP2D6∗4. Eur J Clin Pharmacol 1998; 54: 47-52.
37. Rost KL, Brockmöller J, Esdorn F, Roots I,. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. J Hepatol 1995; 23: 268-277.
38. Ohnishi A, Murakami S, Akizuki S, Mochizuki J, Echizen H, Takagi I,. In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease. J Clin Pharmacol 2005; 45: 1221-1229.
39. Williams ML, Bhargava P, Cherrouk I, Marshall JL, Flockhart DA, Wainer IW,. A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer. Br J Clin Pharmacol 2000; 49: 485-488.
40. Helsby NA, Lo WY, Sharples K, Riley G, Murray M, Spells K, Dzhelai M, Simpson A, Findlay M,. CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype. Br J Cancer 2008; 99: 1251-1255.
41. Ito K, Brown HS, Houston JB,. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 2004; 57: 473-486.
42. Michalets EL,. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84-112.
43. Cavallari LH, Jeong H, Bress A,. Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med 2011; 4: 123-136.
44. Hirota T, Eguchi S, Ieiri I,. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinet 2013; 28: 28-37.
45. Lynch T, Price A,. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007; 76: 391-396.
46. Sindrup SH, Brøsen K,. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 1995; 5: 335-346.
47. Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W,. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther 1997; 62: 334-347.
48. Committee for Medicinal Products for Human Use (CHMP). Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products (EMA/CHMP/37646/2009). European Medicines Agency, London, 12 December 2011. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/02/WC500121954.pdf (last accessed 28 February 2014).
49. Zanger UM, Klein K, Thomas M, Rieger JK, Tremmel R, Kandel BA, Klein M, Magdy T,. Genetics, epigenetics, and regulation of drug-metabolizing cytochrome P450 enzymes. Clin Pharmacol Ther 2014; 95: 258-261.
50. Lockhart P, Guthrie B,. Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis. Br J Gen Pract 2011; 61: e565-572.
51. Preskorn SH, Shah R, Neff M, Golbeck AL, Choi J,. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline. J Psychiatr Pract 2007; 13: 5-12.
52. Lohmann PL, Rao ML, Ludwig M, Griese EU, Zanger UM, Mörike K, Maier W, Bagli M,. Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients. Eur J Clin Pharmacol 2001; 57: 289-295. Erratum in: Eur J Clin Pharmacol 2001; 57: 745.
53. Bramer SL, Suri A,. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol. Clin Pharmacokinet 1999; 37 (Suppl. 2): 41-51.
54. Cai WM, Chen B, Ling SS, Zhang YD,. Terbinafine-associated inhibition of dextromethorphan metabolism in Chinese subjects. Br J Clin Pharmacol 2001; 51: 107-108.
55. Caraco Y, Sheller J, Wood AJ,. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J Pharmacol Exp Ther 1999; 290: 413-422.
56. Kim K, Johnson JA, Derendorf H,. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 2004; 44: 1083-1105.
57. Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M,. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. Pharmacogenetics 1999; 9: 551-559.
58. Shah RR,. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view. Xenobiotica 1993; 23: 1159-1193.
59. Llerena A, Berecz R, de la Rubia A, Fernández-Salguero P, Dorado P,. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther Drug Monit 2001; 23: 616-620.
60. Preskorn SH, Kane CP, Lobello K, Nichols AI, Fayyad R, Buckley G, Focht K, Guico-Pabia CJ,. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry 2013; 74: 614-621.
61. Kumar V, Brundage RC, Oetting WS, Leppik IE, Tracy TS,. Differential genotype dependent inhibition of CYP2C9 in humans. Drug Metab Dispos 2008; 36: 1242-1248.
62. Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T,. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol 2004; 44: 1223-1229.
63. He SM, Zhou ZW, Li XT, Zhou SF,. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. Curr Med Chem 2011; 18: 667-713.
64. Hauta-Aho M, Tirkkonen T, Vahlberg T, Laine K,. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med 2009; 41: 619-628.
65. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA,; for International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
66. Andersson ML, Lindh JD, Mannheimer B,. The impact of interacting drugs on dispensed doses of warfarin in the Swedish population: a novel use of population based drug registers. J Clin Pharmacol 2013; 53: 1322-1327.
67. Santos PCJL, Soares RAG, Strunz CMC, Grinberg M, Ferreira JFM, Cesar LAM, Scanavacca M, Krieger JE, Pereira AC,. Simultaneous use of amiodarone influences warfarin maintenance dose but is not associated with adverse events. J Manag Care Pharm 2014; 20: 376-381.
68. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P,. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113: 784-792.
69. de Souza JA, Olopade OI,. CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine. Semin Oncol 2011; 38: 263-273.
70. Ratain MJ, Nakamura Y, Cox NJ,. CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality. Clin Pharmacol Ther 2013; 94: 185-187.
71. Kelly CM, Pritchard KI,. CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned. J Natl Cancer Inst 2012; 104: 427-428.
72. Zeng Z, Liu Y, Liu Z, You J, Chen Z, Wang J, Peng Q, Xie L, Li R, Li S, Qin X,. CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis. Cancer Chemother Pharmacol 2013; 72: 287-303.
73. Cronin-Fenton DP, Damkier P, Lash TL,. Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol 2014; 10: 107-122.
74. Markkula A, Hjertberg M, Rose C, Ingvar C, Jernström H,. No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients. Acta Oncol 2014; 53: 195-200.
75. Kiyotani K, Mushiroda T, Hosono N, Tsunoda T, Kubo M, Aki F, Okazaki Y, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H,. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet Genomics 2010; 20: 565-568.
76. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, Paszat LF,. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010; 340: c693. doi: 10.1136/bmj.c693.
77. Gschwind L, Rollason V, Boehlen F, Rebsamen M, Combescure C, Grünenwald M, Matthey A, Bonnabry P, Dayer P, Desmeules JA,. Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment. Pharmacogenomics 2013; 14: 745-753.
78. Lindh JD, Holm L, Dahl ML, Alfredsson L, Rane A,. Incidence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis 2008; 25: 151-159.
79. Gasse C, Hollowell J, Meier CR, Haefeli WE,. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 2005; 94: 537-543.
80. Lam J, Gomes T, Juurlink DN, Mamdani MM, Pullenayegum EM, Kearon C, Spencer FA, Paterson M, Zheng H, Holbrook AM,. Hospitalization for hemorrhage among warfarin recipients prescribed amiodarone. Am J Cardiol 2013; 112: 420-423.
81. Ma TK, Lam YY, Tan VP, Yan BP,. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br J Clin Pharmacol 2011; 72: 697-706.
82. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D,. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011; 343: d4588. doi: 10.1136/bmj.d4588.
83. Kreutz RP, Stanek EJ, Aubert R, Yao J, Breall JA, Desta Z, Skaar TC, Teagarden JR, Frueh FW, Epstein RS, Flockhart DA,. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy 2010; 30: 787-796.
84. Ching GG, Li D, Baker WL, Hohl PK, Mather JF, McKay RG, Lundbye JB,. Major adverse cardiac events among postpercutaneous coronary intervention patients on clopidogrel and proton pump inhibitors. Conn Med 2012; 76: 205-211.
85. Burkard T, Kaiser CA, Brunner-La Rocca H, Osswald S, Pfisterer ME, Jeger RV, BASKET Investigators. Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial. J Intern Med 2012; 271: 257-263.
86. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP, COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909-1917.
87. Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, Lardoux H, Coste P, Lefèvre T, Drouet E, Mulak G, Bataille V, Ferrières J, Verstuyft C, Danchin N,. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 2011; 123: 474-482.
88. Schmidt M, Johansen MB, Robertson DJ, Maeng M, Kaltoft A, Jensen LO, Tilsted HH, Bøtker HE, Sørensen HT, Baron JA,. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther 2012; 35: 165-174.
89. Mas-Morey P, Calderõn-Hernanz B, Oliver-Noguera A, Ripoll-Vera T, Vilanova-Boltõ M,. Frequency and outcomes of concomitant use of proton pump inhibitors and clopidogrel after hospital discharge. Therapie 2013; 68: 113-115.
90. Shrestha K, Hughes JD, Lee YP, Parsons R,. The prevalence of co-administration of clopidogrel and proton pump inhibitors. Qual Prim Care 2011; 19: 35-42.
91. Wedemeyer R-S, Blume H,. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf 2014; 37: 201-211.
92. Brauch H, Schwab M,. Prediction of tamoxifen outcome by genetic variation of CYP2D6 in postmenopausal women with early breast cancer. Br J Clin Pharmacol 2014; 77: 695-703.
93. Brauch H, Schwab M,. Re: Damkier: CYP2D6 genotyping and tamoxifen in the treatment of postmenopausal breast cancer. Br J Clin Pharmacol 2014; 78: 433-434.
94. Lane MA, Devine ST, McDonald JR,. High-risk antimicrobial prescriptions among ambulatory patients on warfarin. J Clin Pharm Ther 2012; 37: 157-160.
95. Visser LE, Penning-van Bees FJ, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, Stricker BH,. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002; 88: 705-710.
96. Alderman CP, Hundertmark JD, Soetratma TW,. Interaction of serotonin re-uptake inhibitors with perhexiline. Aust N Z J Psychiatry 1997; 31: 601-603.
97. Sheikh AR, Westley I, Sallustio B, Horowitz JD, Beltrame JF,. Interaction of terbinafine (anti-fungal agent) with perhexiline: a case report. Heart Lung Circ 2014; 23: e149-151.
98. Eichelbaum M, Spannbrucker N, Dengler HJ,. Lack of N-oxidation of sparteine in certain healthy subjects. Proceedings of the Sixth International Congress of Pharmacology, Helsinki, 20-25 July 1975 (Abstract 1071) Oxford: Pergamon Press Ltd, 1977: p 450.
99. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL,. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584-586.
100. Angelo MM, Dring LG, Idle JR, Lancaster R, Mahgoub A, Smith RL,. Defective alicyclic hydroxylation of debrisoquine in man. Proceedings of the British Pharmacological Society, Manchester, 7-9 September 1977. Br J Clin Pharmacol 1977; 4: 725P.
101. Eichelbaum M, Spannbrucker N, Dengler HJ,. Influence of the defective metabolism of sparteine on its pharmacokinetics. Eur J Clin Pharmacol 1979; 16: 189-194.
102. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ,. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16: 183-187.
103. Park BK, Eichelbaum M, Ohnhaus EE,. 6-beta-hydroxycortisol excretion in relation to polymorphic N-oxidation of sparteine. Br J Clin Pharmacol 1982; 13: 737-740.
104. Sachse C, Brockmöller J, Bauer S, Roots I,. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-295.
105. Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C,. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985; 7: 478-480.
106. Bertilsson L, Dahl ML, Sjöqvist F, Aberg-Wistedt A, Humble M, Johansson I, Lundqvist E, Ingelman-Sundberg M,. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341: 63.
107. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M,. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825-11829.
108. Meyer UA,. Pharmacogenetics: the slow, the rapid, and the ultrarapid. Proc Natl Acad Sci USA 1994; 91: 1983-1984.
109. Nordin C, Bertilsson L,. Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline. Clin Pharmacokinet 1995; 28: 26-40.
110. Mura C, Panserat S, Vincent-Viry M, Galteau MM, Jacqz-Aigrain E, Krishnamoorthy R,. DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers. Hum Genet 1993; 92: 367-372.
111. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM,. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000; 10: 577-581.
112. Hertz DL, McLeod HL, Irvin WJ Jr,. Tamoxifen and CYP2D6: a contradiction of data. Oncologist 2012; 17: 620-630.
113. de Graan AJ, Teunissen SF, de Vos FY, Loos WJ, van Schaik RH, de Jongh FE, de Vos AI, van Alphen RJ, van der Holt B, Verweij J, Seynaeve C, Beijnen JH, Mathijssen RH,. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol 2011; 29: 3240-3246.
114. Antunes MV, Linden R, Santos TV, Wallemacq P, Haufroid V, Classen JF, Andreolla H, Costa N, Fontanive TO, Rosa DD,. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy. Ther Drug Monit 2012; 34: 422-431.
115. 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels. Cancer Chemother Pharmacol 2013; 71: 593-601.
116. Trojan A, Vergopoulos A, Breitenstein U, Seifert B, Rageth C, Joechle W,. The discriminatory value of CYP2D6 genotyping in predicting the dextromethorphan/dextrorphan phenotype in women with breast cancer. Breast Care (Basel) 2012; 7: 25-31.
117. Trojan A, Vergopoulos A, Breitenstein U, Tausch C, Seifert B, Joechle W,. CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients. Cancer Chemother Pharmacol 2013; 71: 301-306.
118. Bozkurt A, Basçi NE, Işimer A, Sayal A, Kayaalp SO,. Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study. Eur J Drug Metab Pharmacokinet 1996; 21: 309-314.
119. Streetman DS, Ellis RE, Nafziger AN, Leeder JS, Gaedigk A, Gotschall R, Kearns GL, Bertino JS Jr,. Dose dependency of dextromethorphan for cytochrome P450 (CYP2D6) phenotyping. Clin Pharmacol Ther 1999; 66: 535-541.
120. Frank D, Jaehde U, Fuhr U,. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 2007; 63: 321-333.
121. Ozdemir M, Crewe KH, Tucker GT, Rostami-Hodjegan A,. Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. J Clin Pharmacol 2004; 44: 1398-1404.
122. Hu OY, Tang HS, Lane HY, Chang WH, Hu TM,. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity. J Pharmacol Exp Ther 1998; 285: 955-960.
123. Chládek J, Zimová G, Beránek M, Martínková J,. In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma. Eur J Clin Pharmacol 2000; 56: 651-657.
124. Jurica J, Bartecek R, Zourkova A, Pindurova E, Sulcova A, Kasparek T, Zendulka O,. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice. J Clin Pharm Ther 2012; 37: 486-490.
125. 13C]-dextromethorphan breath test to assess CYP2D6 phenotype. J Clin Pharmacol 2008; 48: 1041-1051.
126. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, Woosley RL, Flockhart DA,. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995; 57: 662-669.
127. Yamada S, Shiohira H, Yasui-Furukori N, Tateishi T, Akamine Y, Uno T,. The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers. Eur J Clin Pharmacol 2013; 69: 1423-1428.
128. 13C]-pantoprazole breath test. J Pharmacol Exp Ther 2009; 329: 297-305.
129. 13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole. Aliment Pharmacol Ther 2009; 30: 294-300.
130. Cheng J, Zhen Y, Miksys S, Beyoʇlu D, Krausz KW, Tyndale RF, Yu A, Idle JR, Gonzalez FJ,. Potential role of CYP2D6 in the central nervous system. Xenobiotica 2013; 43: 973-984.
131. Wang X, Li J, Dong G, Yue J,. The endogenous substrates of brain CYP2D6. Eur J Pharmacol 2013; 724: 211-218.
132. Haduch A, Bromek E, Daniel WA,. Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters. Pharmacol Reports 2013; 65: 1519-1528.
133. Yu AM, Idle JR, Herraiz T, Küpfer A, Gonzalez FJ,. Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 2003; 13: 307-319.
134. Yu AM, Idle JR, Byrd LG, Krausz KW, Küpfer A, Gonzalez FJ,. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003; 13: 173-181.
135. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER 3rd, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA 3rd, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH, COAG Investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013; 369: 2283-2293.
136. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlström B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M, EU-PACT Group. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013; 369: 2294-2303.
137. Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, Konstantinides S, Le Cessie S, Maltezos E, van der Meer FJ, Redekop WK, Remkes M, Rosendaal FR, van Schie RM, Tavridou A, Tziakas D, Wadelius M, Manolopoulos VG, Maitland-van der Zee AH, EU-PACT Group. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med 2013; 369: 2304-2312.
138. Ieiri I, Yamada S, Seto K, Morita T, Kaneda T, Mamiya K, Tashiro N, Higuchi S, Otsubo K,. A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients. Pharmacopsychiatry 2003; 36: 192-196.
139. Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA, Adson DE,. Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 2005; 25: 226-229.
140. Güzey C, Norström A, Spigset O,. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther Drug Monit 2002; 24: 436-437.
141. Shiran MR, Chowdry J, Rostami-Hodjegan A, Ellis SW, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT,. A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol 2003; 56: 220-224.
142. Abdel-Rahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL,. Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clin Pharmacol Ther 1999; 65: 465-472.
143. Zourková A, Hadasová E,. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects. Gen Physiol Biophys 2003; 22: 103-113.
144. Köhler D, Härtter S, Fuchs K, Sieghart W, Hiemke C,. CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics 1997; 7: 453-461.
145. Liston HL, DeVane CL, Boulton DW, Risch SC, Markowitz JS, Goldman J,. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol 2002; 22: 169-173.
146. Madani S, Barilla D, Cramer J, Wang Y, Paul C,. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J Clin Pharmacol 2002; 42: 1211-1218.
147. Juřica J, Žourková A,. Dynamics and persistence of CYP2D6 inhibition by paroxetine. J Clin Pharm Ther 2013; 38: 294-300.